골다공증 치료제 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2033년)

Osteoporosis Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033

US $ 4,995 ￦ 6,970,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295 ￦ 10,179,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495 ￦ 11,853,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

한글목차

Persistence Market Research는 이번에 세계의 골다공증 치료제 시장에 관한 광범위한 리포트를 발행했습니다. 촉진요인·동향·기회·과제 등의 주요 시장 역학을 종합적으로 분석하고, 시장 구조에 관한 심층 인사이트를 제공하고 있습니다.

주요 인사이트

• 골다공증 치료제 시장 규모(2024년) : 1,390만 달러
• 시장 예측 금액(2033년) : 1,890만 달러
• 세계 시장 성장률(CAGR 2024-2033년) : 3.5%

골다공증 치료제 시장 - 리포트 범위 :

골다공증 치료제 시장은 뼈가 약해지고 골절 위험이 높아지는 골다공증을 예방하고 치료하기 위한 다양한 의약품을 포괄합니다. 골다공증 치료제는 특히 폐경 후 여성, 노인 및 기타 고위험군 환자에서 골다공증 관리에 매우 중요한 역할을 합니다. 이 시장은 병원, 클리닉, 전문 약국 등 다양한 부문에 서비스를 제공합니다. 성장의 원동력은 골다공증 유병률 증가, 약물 제형의 발전, 다양한 의료 현장에서의 예방적 헬스케어 대책의 적용 확대입니다.

시장 성장의 촉진요인:

세계 골다공증 치료제 시장을 주도하는 몇 가지 주요 요인이 있습니다. 전 세계에서 골다공증 발병률이 증가함에 따라 더 많은 환자들이 효과적인 치료 옵션을 필요로 하고 있으며, 시장 성장을 가속하고 있습니다. 또한 단일 클론 항체 및 선택적 에스트로겐 수용체 조절제 개발과 같은 약물 제제의 기술적 발전은 골다공증 치료의 효과와 안전성을 향상시켜 시장 성장에 더욱 박차를 가하고 있습니다. 또한 뼈 건강에 대한 인식이 높아지고 스크리닝 프로그램의 가용성이 증가함에 따라 수요를 촉진하고 있습니다. 연구개발의 강화와 혁신적인 치료법의 도입은 다양한 의료적 요구를 가진 환자들에게 더 나은 솔루션을 제공하여 시장 성장에 기여하고 있습니다.

시장 성장 억제요인 :

골다공증 치료제 시장은 유망한 성장세를 보이고 있지만, 첨단 치료제의 높은 비용과 비스포스포네이트 제제 등 특정 약물의 잠재적 부작용에 대한 우려로 인해 어려움을 겪고 있습니다. 또한 생활습관 개선, 비약리학적 중재 등 비침습적이라는 이유로 일부 의료진이 선호하는 대체 치료 옵션의 가용성이 시장 성장을 저해하는 요인으로 작용할 수 있습니다. 또한 자원이 부족한 환경에서 첨단 약물 치료에 대한 접근성에 대한 우려도 시장 확대에 걸림돌로 작용하고 있습니다. 이러한 문제를 해결하기 위해서는 골다공증 치료제의 안전성, 가격, 접근성을 개선하기 위한 연구개발에 대한 지속적인 투자가 필요합니다.

시장 기회 :

이 시장은 환자의 예후를 개선하는 생물학적 제제 및 병용요법의 채택 확대가 큰 비즈니스 기회로 작용하고 있습니다. 서방형 제제 및 주사제 등 첨단 약물전달 시스템의 개발은 보다 편리하고 효과적인 치료 옵션에 대한 수요 증가에 대응하고 있습니다. 신흥 시장의 의료 인프라 확대는 시장 성장을 위한 새로운 채널을 제공하고, 더 많은 환자들에게 첨단 골다공증 치료제를 제공할 수 있는 기회를 제공할 수 있습니다. 전략적 파트너십, 환자 교육 프로그램에 대한 투자, 맞춤형 의료 접근 방식을 채택하는 것은 새로운 기회를 활용하고 시장 리더십을 유지하는 데 필수적입니다.

이 보고서에서 다룬 주요 질문

• 세계 골다공증 치료제 시장의 성장을 가속하는 주요 요인은?
• 골다공증 치료제의 유형과 제형은 어떤 유형과 제형이 다양한 의료 환경에서 사용되고 있는가?
• 기술의 발전은 골다공증 치료제 시장 경쟁 구도에 어떤 영향을 미치고 있는가?
• 골다공증 치료제 시장의 주요 기업은 어디에 있으며, 경쟁력을 유지하기 위해 어떤 전략을 취하고 있는가?
• 세계 골다공증 치료제 시장의 새로운 동향과 전망은?

목차

제1장 개요

제2장 시장 개요

• 시장 범위 / 분류
• 시장의 정의 / 범위 / 제한
• 포함 사항·제외 사항

제3장 주요 시장 동향

• 시장에 영향을 미치는 주요 동향
• 혁신 / 개발 동향

제4장 주요 성공 요인

• 약제 채택 분석
• 주요 규제
• 최근 의약품의 발매 / 승인
• 파이프라인 평가
• PESTEL 분석
• 밸류체인 분석
• 주요 프로모션 전략 : 주요 기업별

제5장 시장 배경

• 거시경제 요인
• 예측 요인 - 관련성과 영향
• 시장 역학

제6장 COVID-19 위기 분석

• COVID-19와 영향 분석
  • 약제별
  • 유통 채널별
  • 국가별
• 2022년 시장 시나리오

제7장 세계의 골다공증 치료제 시장 수요(금액 또는 규모, 백만 달러) 분석

• 과거 시장 금액(백만 달러) 분석, 2019-2023년
• 현재 및 향후 시장 금액(백만 달러) 예측, 2024-2033년
  • 전년대비 성장 동향 분석
  • 절대액 기회 분석

제8장 세계의 골다공증 치료제 시장 분석, 약제별

• 서론 / 주요 조사 결과
• 과거 시장 규모(백만 달러) 분석, 약제별, 2019-2023년
• 현재 및 향후 시장 규모(백만 달러) 분석과 예측, 약제별, 2024-2033년
  • 비스포스포네이트
  • 부갑상선 호르몬 요법약
  • 칼시토닌
  • 선택적 에스트로겐 수용체 모듈레이터(SERM)
  • RANK 리간드 저해제
• 시장의 매력 분석 : 약제별

제9장 세계의 골다공증 치료제 시장 분석, 유통 채널별

• 서론 / 주요 조사 결과
• 과거 시장 규모(백만 달러) 분석, 유통 채널별, 2019-2023년
• 현재 및 향후 시장 규모(백만 달러) 분석과 예측, 유통 채널별, 2024-2033년
  • 소매 약국
  • 병원 약국
  • 온라인 판매
• 시장의 매력 분석 : 유통 채널별

제10장 세계의 골다공증 치료제 시장 분석, 지역별

• 서론
• 과거 시장 규모(백만 달러) 분석, 지역별, 2019-2023년
• 현재 및 향후 시장 금액(백만 달러) 분석과 예측, 지역별, 2024-2033년
  • 북미
  • 라틴아메리카
  • 유럽
  • 동아시아
  • 남아시아
  • 오세아니아
  • 중동 및 아프리카(MEA)
• 시장의 매력 분석 : 지역별

제11장 북미의 골다공증 치료제 시장 분석

제12장 라틴아메리카의 골다공증 치료제 시장 분석

제13장 유럽의 골다공증 치료제 시장 분석

제14장 동아시아의 골다공증 치료제 시장 분석

제15장 남아시아의 골다공증 치료제 시장 분석

제16장 오세아니아의 골다공증 치료제 시장

제17장 중동 및 아프리카(MEA)의 골다공증 치료제 시장 분석

제18장 시장 구조 분석

• 시장 분석 : 기업 계층별
• 주요 기업의 시장 점유율 분석
• 시장 입지 분석

제19장 경쟁 분석

• 경쟁 대시보드
• 경쟁 상세 정보
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Merck &Co, Inc.
  • Novartis AG
  • Amgen, Inc.
  • Novo Nordisk A/S
  • Actavis plc
  • Pfizer, Inc.
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd
  • Enzene Biosciences Ltd
  • Theramex

제20장 사용되는 전제 조건과 두자어

제21장 조사 방법

KSA

영문 목차

영문목차

Persistence Market Research has recently published an extensive report on the global Osteoporosis Drugs Market. This report offers a comprehensive analysis of the key market dynamics, including drivers, trends, opportunities, and challenges, providing deep insights into the market structure.

Key Insights:

• Osteoporosis Drugs Market Size (2024E): US$ 13.9 Mn
• Projected Market Value (2033F): US$ 18.9 Mn
• Global Market Growth Rate (CAGR 2024 to 2033): 3.5%

Osteoporosis Drugs Market - Report Scope:

The Osteoporosis Drugs Market encompasses a variety of pharmaceutical treatments aimed at preventing and treating osteoporosis, a condition characterized by weakened bones and an increased risk of fractures. These drugs are critical in managing the disease, particularly among postmenopausal women, the elderly, and others at high risk. The market serves diverse segments, including hospitals, clinics, and specialty pharmacies. Growth is driven by the increasing prevalence of osteoporosis, advancements in drug formulations, and the expanding application of preventive healthcare measures across various healthcare settings.

Market Growth Drivers:

Several key factors are driving the global Osteoporosis Drugs Market. The rising incidence of osteoporosis globally boosts the market's growth as more patients require effective treatment options. Technological advancements in drug formulations, such as the development of monoclonal antibodies and selective estrogen receptor modulators, have improved the efficacy and safety of osteoporosis treatments, further fueling market expansion. Additionally, the growing awareness of bone health and the increasing availability of screening programs drive demand. Enhanced research and development activities, along with the introduction of innovative therapies, contribute to market growth by offering more tailored solutions for patients with different medical needs.

Market Restraints:

Despite promising growth prospects, the Osteoporosis Drugs Market faces challenges related to the high costs of advanced drug treatments and potential side effects associated with certain medications, such as bisphosphonates. Market growth can be hindered by the availability of alternative treatment options, such as lifestyle modifications and non-pharmacological interventions, which may be preferred by some healthcare providers due to their non-invasive nature. Additionally, concerns about the accessibility of advanced drug treatments in low-resource settings pose challenges for market expansion. Addressing these issues requires ongoing investment in research and development to improve the safety, affordability, and accessibility of osteoporosis drugs.

Market Opportunities:

The market presents significant opportunities driven by the increasing adoption of biologic drugs and combination therapies, which offer improved patient outcomes. The development of advanced drug delivery systems, such as extended-release formulations and injectable therapies, caters to the growing need for more convenient and effective treatment options. The expansion of healthcare infrastructure in emerging markets provides new channels for market growth, allowing companies to reach a broader patient population and offer access to cutting-edge osteoporosis treatments. Strategic partnerships, investments in patient education programs, and the introduction of personalized medicine approaches are essential for capitalizing on emerging opportunities and maintaining market leadership.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the Osteoporosis Drugs Market globally?
• Which types and formulations of osteoporosis drugs are leading the adoption in various healthcare settings?
• How are technological advancements influencing the competitive landscape of the Osteoporosis Drugs Market?
• Who are the key players in the Osteoporosis Drugs Market, and what strategies are they employing to stay competitive?
• What are the emerging trends and future prospects in the global Osteoporosis Drugs Market?

Competitive Intelligence and Business Strategy:

Leading players in the global Osteoporosis Drugs Market, including Amgen Inc., Eli Lilly and Company, and Merck & Co., focus on innovation, product differentiation, and strategic collaborations to gain a competitive edge. These companies invest in R&D to develop advanced osteoporosis treatments and explore new drug delivery systems. Collaborations with healthcare providers, research institutions, and technology developers facilitate market access and promote new product adoption. Emphasis on patient education, high-quality products, and comprehensive training programs fosters market growth and enhances brand loyalty in the evolving Osteoporosis Drugs Market landscape.

Key Companies Profiled:

• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Merck & Co, Inc.
• Novartis AG
• Amgen, Inc.
• Novo Nordisk A/S
• Actavis plc
• Pfizer, Inc.
• GlaxoSmithKline plc
• Teva Pharmaceutical Industries Ltd
• Enzene Biosciences Ltd
• Theramex

Osteoporosis Drugs Market Industry Segmentation

Drug:

• Bisphosphonates
• Parathyroid Hormone Therapy Drugs
• Calcitonin
• Selective Oestrogen Receptors Modulators (SERMs)
• RANK Ligand Inhibitors

Distribution Channel:

• Retail Pharmacies
• Hospital Pharmacies
• Online Sales

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Market Outlook
• 1.2. Demand Side Trends
• 1.3. Supply Side Trends
• 1.4. Analysis and Recommendations

2. Market Overview

• 2.1. Market Coverage / Taxonomy
• 2.2. Market Definition / Scope / Limitations
• 2.3. Inclusions and Exclusions

3. Key Market Trends

• 3.1. Key Trends Impacting the Market
• 3.2. Innovation / Development Trends

4. Key Success Factors

• 4.1. Drug Adoption Analysis
• 4.2. Key Regulations
• 4.3. Recent Drug launches/ Approvals
• 4.4. Pipeline Assessment
• 4.5. PESTEL Analysis
• 4.6. Value Chain Analysis
• 4.7. Key Promotional Strategies, By Key Players

5. Market Background

• 5.1. Macro-Economic Factors
  • 5.1.1. Global GDP Growth Outlook
  • 5.1.2. Global Healthcare Outlook
  • 5.1.3. Global Orthopedic Drugs & Devices market outlook
• 5.2. Forecast Factors - Relevance & Impact
  • 5.2.1. Increase in R&D Spending
  • 5.2.2. Growing Osteoarthritis Prevalence
  • 5.2.3. Cost of Drug
  • 5.2.4. Drug Features
  • 5.2.5. New Drug Pipeline
  • 5.2.6. Changes in Regulatory Policies
  • 5.2.7. Strategic Collaborations amongst Players
• 5.3. Market Dynamics
  • 5.3.1. Drivers
  • 5.3.2. Restraints
  • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

• 6.1. COVID-19 and Impact Analysis
  • 6.1.1. By Drug
  • 6.1.2. By Distribution Channel
  • 6.1.3. By Country
• 6.2. 2022 Market Scenario

7. Global Osteoporosis Drugs Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2033

• 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
• 7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2033
  • 7.2.1. Y-o-Y Growth Trend Analysis
  • 7.2.2. Absolute $ Opportunity Analysis

8. Global Osteoporosis Drugs Market Analysis 2019-2023 and Forecast 2024-2033, By Drug

• 8.1. Introduction / Key Findings
• 8.2. Historical Market Size (US$ Mn) Analysis By Drug, 2019-2023
• 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug, 2024-2033
  • 8.3.1. Bisphosphonates
  • 8.3.2. Parathyroid Hormone Therapy Drugs
  • 8.3.3. Calcitonin
  • 8.3.4. Selective Estrogen Receptors Modulators (SERMs)
  • 8.3.5. RANK Ligand Inhibitors
• 8.4. Market Attractiveness Analysis By Drug

9. Global Osteoporosis Drugs Market Analysis 2019-2023 and Forecast 2024-2033, By Distribution Channel

• 9.1. Introduction / Key Findings
• 9.2. Historical Market Size (US$ Mn) Analysis, By Distribution Channel, 2019-2023
• 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2024-2033
  • 9.3.1. Retail Pharmacies
  • 9.3.2. Hospital Pharmacies
  • 9.3.3. Online Sales
• 9.4. Market Attractiveness Analysis By Distribution Channel

10. Global Osteoporosis Drugs Market Analysis 2019-2023 and Forecast 2024-2033, By Region

• 10.1. Introduction
• 10.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2023
• 10.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, By Region 2024-2033
  • 10.3.1. North America
  • 10.3.2. Latin America
  • 10.3.3. Europe
  • 10.3.4. East Asia
  • 10.3.5. South Asia
  • 10.3.6. Oceania
  • 10.3.7. Middle East and Africa (MEA)
• 10.4. Market Attractiveness Analysis By Region

11. North America Osteoporosis Drugs Market Analysis 2019-2023 and Forecast 2024-2033

• 11.1. Introduction
• 11.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 11.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
  • 11.3.1. By Country
    • 11.3.1.1. U.S.
    • 11.3.1.2. Canada
  • 11.3.2. By Drug
  • 11.3.3. By Distribution Channel
• 11.4. Market Attractiveness Analysis
  • 11.4.1. By Country
  • 11.4.2. By Drug
  • 11.4.3. By Distribution Channel
• 11.5. Market Trends
• 11.6. Drivers and Restraints - Impact Analysis
• 11.7. Key Players - Intensity Mapping
• 11.8. Country Level Analysis & Forecast
  • 11.8.1. U.S. Osteoporosis Drugs Market Analysis
    • 11.8.1.1. Introduction
    • 11.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 11.8.1.2.1. By Drug
      • 11.8.1.2.2. By Distribution Channel
  • 11.8.2. Canada Osteoporosis Drugs Market Analysis
    • 11.8.2.1. Introduction
    • 11.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 11.8.2.2.1. By Drug
      • 11.8.2.2.2. By Distribution Channel

12. Latin America Osteoporosis Drugs Market Analysis 2019-2023 and Forecast 2024-2033

• 12.1. Introduction
• 12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 12.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
  • 12.3.1. By Country
    • 12.3.1.1. Mexico
    • 12.3.1.2. Brazil
    • 12.3.1.3. Argentina
    • 12.3.1.4. Rest of Latin America
  • 12.3.2. By Drug
  • 12.3.3. By Distribution Channel
• 12.4. Market Attractiveness Analysis
  • 12.4.1. By Country
  • 12.4.2. By Drug
  • 12.4.3. By Distribution Channel
• 12.5. Market Trends
• 12.6. Drivers and Restraints - Impact Analysis
• 12.7. Key Players - Intensity Mapping
• 12.8. Country Level Analysis & Forecast
  • 12.8.1. Mexico Osteoporosis Drugs Market Analysis
    • 12.8.1.1. Introduction
    • 12.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 12.8.1.2.1. By Drug
      • 12.8.1.2.2. By Distribution Channel
  • 12.8.2. Brazil Osteoporosis Drugs Market Analysis
    • 12.8.2.1. Introduction
    • 12.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 12.8.2.2.1. By Drug
      • 12.8.2.2.2. By Distribution Channel
  • 12.8.3. Argentina Osteoporosis Drugs Market Analysis
    • 12.8.3.1. Introduction
    • 12.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 12.8.3.2.1. By Drug
      • 12.8.3.2.2. By Distribution Channel

13. Europe Osteoporosis Drugs Market Analysis 2019-2023 and Forecast 2024-2033

• 13.1. Introduction
• 13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 13.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
  • 13.3.1. By Country
    • 13.3.1.1. Germany
    • 13.3.1.2. Italy
    • 13.3.1.3. France
    • 13.3.1.4. U.K.
    • 13.3.1.5. Spain
    • 13.3.1.6. BENELUX
    • 13.3.1.7. Russia
    • 13.3.1.8. Rest of Europe
  • 13.3.2. By Drug
  • 13.3.3. By Distribution Channel
• 13.4. Market Attractiveness Analysis
  • 13.4.1. By Country
  • 13.4.2. By Drug
  • 13.4.3. By Distribution Channel
• 13.5. Market Trends
• 13.6. Drivers and Restraints - Impact Analysis
• 13.7. Key Players - Intensity Mapping
• 13.8. Country Level Analysis & Forecast
  • 13.8.1. Germany Osteoporosis Drugs Market Analysis
    • 13.8.1.1. Introduction
    • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.1.2.1. By Drug
      • 13.8.1.2.2. By Distribution Channel
  • 13.8.2. Italy Osteoporosis Drugs Market Analysis
    • 13.8.2.1. Introduction
    • 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.2.2.1. By Drug
      • 13.8.2.2.2. By Distribution Channel
  • 13.8.3. France Osteoporosis Drugs Market Analysis
    • 13.8.3.1. Introduction
    • 13.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.3.2.1. By Drug
      • 13.8.3.2.2. By Distribution Channel
  • 13.8.4. U.K. Osteoporosis Drugs Market Analysis
    • 13.8.4.1. Introduction
    • 13.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.4.2.1. By Drug
      • 13.8.4.2.2. By Distribution Channel
  • 13.8.5. Spain Osteoporosis Drugs Market Analysis
    • 13.8.5.1. Introduction
    • 13.8.5.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.5.2.1. By Drug
      • 13.8.5.2.2. By Distribution Channel
  • 13.8.6. BENELUX Osteoporosis Drugs Market Analysis
    • 13.8.6.1. Introduction
    • 13.8.6.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.6.2.1. By Drug
      • 13.8.6.2.2. By Distribution Channel
  • 13.8.7. Russia Osteoporosis Drugs Market Analysis
    • 13.8.7.1. Introduction
    • 13.8.7.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.7.2.1. By Drug
      • 13.8.7.2.2. By Distribution Channel

14. East Asia Osteoporosis Drugs Market Analysis 2019-2023 and Forecast 2024-2033

• 14.1. Introduction
• 14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 14.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
  • 14.3.1. By Country
    • 14.3.1.1. China
    • 14.3.1.2. Japan
    • 14.3.1.3. South Korea
  • 14.3.2. By Drug
  • 14.3.3. By Distribution Channel
• 14.4. Market Attractiveness Analysis
  • 14.4.1. By Country
  • 14.4.2. By Drug
  • 14.4.3. By Distribution Channel
• 14.5. Market Trends
• 14.6. Drivers and Restraints - Impact Analysis
• 14.7. Key Players - Intensity Mapping
• 14.8. Country Level Analysis & Forecast
  • 14.8.1. China Osteoporosis Drugs Market Analysis
    • 14.8.1.1. Introduction
    • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.1.2.1. By Drug
      • 14.8.1.2.2. By Distribution Channel
  • 14.8.2. Japan Osteoporosis Drugs Market Analysis
    • 14.8.2.1. Introduction
    • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.2.2.1. By Drug
      • 14.8.2.2.2. By Distribution Channel
  • 14.8.3. South Korea Osteoporosis Drugs Market Analysis
    • 14.8.3.1. Introduction
    • 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.3.2.1. By Drug
      • 14.8.3.2.2. By Distribution Channel

15. South Asia Osteoporosis Drugs Market Analysis 2019-2023 and Forecast 2024-2033

• 15.1. Introduction
• 15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 15.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
  • 15.3.1. By Country
    • 15.3.1.1. India
    • 15.3.1.2. Indonesia
    • 15.3.1.3. Malaysia
    • 15.3.1.4. Thailand
    • 15.3.1.5. Rest of South Asia
  • 15.3.2. By Drug
  • 15.3.3. By Distribution Channel
• 15.4. Market Attractiveness Analysis
  • 15.4.1. By Country
  • 15.4.2. By Drug
  • 15.4.3. By Distribution Channel
• 15.5. Market Trends
• 15.6. Drivers and Restraints - Impact Analysis
• 15.7. Key Players - Intensity Mapping
• 15.8. Country Level Analysis & Forecast
  • 15.8.1. India Osteoporosis Drugs Market Analysis
    • 15.8.1.1. Introduction
    • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.1.2.1. By Drug
      • 15.8.1.2.2. By Distribution Channel
  • 15.8.2. Indonesia Osteoporosis Drugs Market Analysis
    • 15.8.2.1. Introduction
    • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.2.2.1. By Drug
      • 15.8.2.2.2. By Distribution Channel
  • 15.8.3. Malaysia Osteoporosis Drugs Market Analysis
    • 15.8.3.1. Introduction
    • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.3.2.1. By Drug
      • 15.8.3.2.2. By Distribution Channel
  • 15.8.4. Thailand Osteoporosis Drugs Market Analysis
    • 15.8.4.1. Introduction
    • 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.4.2.1. By Drug
      • 15.8.4.2.2. By Distribution Channel

16. Oceania Osteoporosis Drugs Market 2019-2023 and Forecast 2024-2033

• 16.1. Introduction
• 16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 16.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
  • 16.3.1. By Country
    • 16.3.1.1. Australia
    • 16.3.1.2. New Zealand
  • 16.3.2. By Drug
  • 16.3.3. By Distribution Channel
• 16.4. Market Attractiveness Analysis
  • 16.4.1. By Country
  • 16.4.2. By Drug
  • 16.4.3. By Distribution Channel
• 16.5. Market Trends
• 16.6. Drivers and Restraints - Impact Analysis
• 16.7. Key Players - Intensity Mapping
• 16.8. Country Level Analysis & Forecast
  • 16.8.1. Australia Osteoporosis Drugs Market Analysis
    • 16.8.1.1. Introduction
    • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.1.2.1. By Drug
      • 16.8.1.2.2. By Distribution Channel
  • 16.8.2. New Zealand Osteoporosis Drugs Market Analysis
    • 16.8.2.1. Introduction
    • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.2.2.1. By Drug
      • 16.8.2.2.2. By Distribution Channel

17. Middle East and Africa (MEA) Osteoporosis Drugs Market Analysis 2019-2023 and Forecast 2024-2033

• 17.1. Introduction
• 17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 17.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
  • 17.3.1. By Country
    • 17.3.1.1. GCC Countries
    • 17.3.1.2. Turkey
    • 17.3.1.3. North Africa
    • 17.3.1.4. South Africa
    • 17.3.1.5. Rest of Middle East and Africa
  • 17.3.2. By Drug
  • 17.3.3. By Distribution Channel
• 17.4. Market Attractiveness Analysis
  • 17.4.1. By Country
  • 17.4.2. By Drug
  • 17.4.3. By Distribution Channel
• 17.5. Market Trends
• 17.6. Drivers and Restraints - Impact Analysis
• 17.7. Key Players - Intensity Mapping
• 17.8. Country Level Analysis & Forecast
  • 17.8.1. GCC Countries Osteoporosis Drugs Market Analysis
    • 17.8.1.1. Introduction
    • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.1.2.1. By Drug
      • 17.8.1.2.2. By Distribution Channel
  • 17.8.2. Turkey Osteoporosis Drugs Market Analysis
    • 17.8.2.1. Introduction
    • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.2.2.1. By Drug
      • 17.8.2.2.2. By Distribution Channel
  • 17.8.3. South Africa Osteoporosis Drugs Market Analysis
    • 17.8.3.1. Introduction
    • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.3.2.1. By Drug
      • 17.8.3.2.2. By Distribution Channel
  • 17.8.4. North Africa Osteoporosis Drugs Market Analysis
    • 17.8.4.1. Introduction
    • 17.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.4.2.1. By Drug
      • 17.8.4.2.2. By Distribution Channel

18. Market Structure Analysis

• 18.1. Market Analysis by Tier of Companies
• 18.2. Market Share Analysis of Top Players
• 18.3. Market Presence Analysis

19. Competition Analysis

• 19.1. Competition Dashboard
• 19.2. Competition Deep Dive
  • 19.2.1. Eli Lilly and Company
    • 19.2.1.1. Overview
    • 19.2.1.2. Product Portfolio
    • 19.2.1.3. Sales Footprint
    • 19.2.1.4. Key Financials
    • 19.2.1.5. SWOT Analysis
    • 19.2.1.6. Strategy Overview
      • 19.2.1.6.1. Marketing Strategy
      • 19.2.1.6.2. Product Strategy
      • 19.2.1.6.3. Channel Strategy
  • 19.2.2. F. Hoffmann-La Roche Ltd.
    • 19.2.2.1. Overview
    • 19.2.2.2. Product Portfolio
    • 19.2.2.3. Sales Footprint
    • 19.2.2.4. Key Financials
    • 19.2.2.5. SWOT Analysis
    • 19.2.2.6. Strategy Overview
      • 19.2.2.6.1. Marketing Strategy
      • 19.2.2.6.2. Product Strategy
      • 19.2.2.6.3. Channel Strategy
  • 19.2.3. Merck & Co, Inc.
    • 19.2.3.1. Overview
    • 19.2.3.2. Product Portfolio
    • 19.2.3.3. Sales Footprint
    • 19.2.3.4. Key Financials
    • 19.2.3.5. SWOT Analysis
    • 19.2.3.6. Strategy Overview
      • 19.2.3.6.1. Marketing Strategy
      • 19.2.3.6.2. Product Strategy
      • 19.2.3.6.3. Channel Strategy
  • 19.2.4. Novartis AG
    • 19.2.4.1. Overview
    • 19.2.4.2. Product Portfolio
    • 19.2.4.3. Sales Footprint
    • 19.2.4.4. Key Financials
    • 19.2.4.5. SWOT Analysis
    • 19.2.4.6. Strategy Overview
      • 19.2.4.6.1. Marketing Strategy
      • 19.2.4.6.2. Product Strategy
      • 19.2.4.6.3. Channel Strategy
  • 19.2.5. Amgen, Inc.
    • 19.2.5.1. Overview
    • 19.2.5.2. Product Portfolio
    • 19.2.5.3. Sales Footprint
    • 19.2.5.4. Key Financials
    • 19.2.5.5. SWOT Analysis
    • 19.2.5.6. Strategy Overview
      • 19.2.5.6.1. Marketing Strategy
      • 19.2.5.6.2. Product Strategy
      • 19.2.5.6.3. Channel Strategy
  • 19.2.6. Novo Nordisk A/S
    • 19.2.6.1. Overview
    • 19.2.6.2. Product Portfolio
    • 19.2.6.3. Sales Footprint
    • 19.2.6.4. Key Financials
    • 19.2.6.5. SWOT Analysis
    • 19.2.6.6. Strategy Overview
      • 19.2.6.6.1. Marketing Strategy
      • 19.2.6.6.2. Product Strategy
      • 19.2.6.6.3. Channel Strategy
  • 19.2.7. Actavis plc
    • 19.2.7.1. Overview
    • 19.2.7.2. Product Portfolio
    • 19.2.7.3. Sales Footprint
    • 19.2.7.4. Key Financials
    • 19.2.7.5. SWOT Analysis
    • 19.2.7.6. Strategy Overview
      • 19.2.7.6.1. Marketing Strategy
      • 19.2.7.6.2. Product Strategy
      • 19.2.7.6.3. Channel Strategy
  • 19.2.8. Pfizer, Inc.
    • 19.2.8.1. Overview
    • 19.2.8.2. Product Portfolio
    • 19.2.8.3. Sales Footprint
    • 19.2.8.4. Key Financials
    • 19.2.8.5. SWOT Analysis
    • 19.2.8.6. Strategy Overview
      • 19.2.8.6.1. Marketing Strategy
      • 19.2.8.6.2. Product Strategy
      • 19.2.8.6.3. Channel Strategy
  • 19.2.9. GlaxoSmithKline plc
    • 19.2.9.1. Overview
    • 19.2.9.2. Product Portfolio
    • 19.2.9.3. Sales Footprint
    • 19.2.9.4. Key Financials
    • 19.2.9.5. SWOT Analysis
    • 19.2.9.6. Strategy Overview
      • 19.2.9.6.1. Marketing Strategy
      • 19.2.9.6.2. Product Strategy
      • 19.2.9.6.3. Channel Strategy
  • 19.2.10. Teva Pharmaceutical Industries Ltd
    • 19.2.10.1. Overview
    • 19.2.10.2. Product Portfolio
    • 19.2.10.3. Sales Footprint
    • 19.2.10.4. Key Financials
    • 19.2.10.5. SWOT Analysis
    • 19.2.10.6. Strategy Overview
      • 19.2.10.6.1. Marketing Strategy
      • 19.2.10.6.2. Product Strategy
      • 19.2.10.6.3. Channel Strategy
  • 19.2.11. Enzene Biosciences Ltd
    • 19.2.11.1. Overview
    • 19.2.11.2. Product Portfolio
    • 19.2.11.3. Sales Footprint
    • 19.2.11.4. Key Financials
    • 19.2.11.5. SWOT Analysis
    • 19.2.11.6. Strategy Overview
      • 19.2.11.6.1. Marketing Strategy
      • 19.2.11.6.2. Product Strategy
      • 19.2.11.6.3. Channel Strategy
  • 19.2.12. Theramex
    • 19.2.12.1. Overview
    • 19.2.12.2. Product Portfolio
    • 19.2.12.3. Sales Footprint
    • 19.2.12.4. Key Financials
    • 19.2.12.5. SWOT Analysis
    • 19.2.12.6. Strategy Overview
      • 19.2.12.6.1. Marketing Strategy
      • 19.2.12.6.2. Product Strategy
      • 19.2.12.6.3. Channel Strategy

20. Assumptions and Acronyms Used

21. Research Methodology

관련자료